GlassScriptPhysician profile
Sayeeda Fatima
NPI 1609134303
$1,736.90
in general payments reported to CMS, 2019-2025
21 companies · $387 in 2025
The $387 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269 · 2020: $62.09 · 2021: $201 · 2022: $219 · 2023: $244 · 2024: $353 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $985.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $984.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $343.40 | 2019-2025 | Cequa |
| Johnson & Johnson Vision Care, INC. | $254.70 | 2021-2025 | Acuvue |
| Novartis Pharmaceuticals Corporation | $222.78 | 2019-2022 | |
| Alcon Vision LLC | $149.50 | 2022-2025 | Clareon |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $113.64 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $112.55 | 2023-2025 | Vyzulta, Miebo, Prolensa |
| Tarsus Pharmaceuticals, INC. | $93.35 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $86.43 | 2024-2025 | Tearcare System, Sion Surgical Instrument, Omni Surgical System |
| Abbvie INC. | $48.82 | 2025 | |
| Dompe US, INC. | $48.54 | 2024-2025 | Oxervate |
| Glaukos Corporation | $47.18 | 2021-2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Aerie Pharmaceuticals, INC. | $43.00 | 2020-2021 | |
| Thea Pharma INC. | $38.64 | 2025 | Iyuzeh |
| Rayner Intraocular Lenses Limited | $27.84 | 2024 | Rayone Emv, Rayone Spheric, Rayone Aspheric |
| Apellis Pharmaceuticals, INC. | $21.57 | 2025 | Syfovre |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $20.06 | 2025 | Tepezza |
| Horizon Therapeutics Plc | $14.05 | 2022 | |
| Shire North American Group INC | $13.34 | 2019 | |
| Harrow Eye, LLC | $13.19 | 2023 | Iheezo |
| Allergan, INC. | $12.28 | 2022 | |
| Galderma Laboratories, L.P. | $12.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sayeeda Fatima listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.